악성종양 환자에서 Cisplatin 병용 화학요법시 Ondansetron의 오심 및 구토 억제 효과
Effect of Ondansetron in the Prevention of Nausea and Vomiting Associated with Cisplatin Chemotherapy in Cancer Patients
대한암학회지 1993년 25권 2호 p.299 ~ 306
소속 상세정보
신상원
최경묵/연종은/박상면/최철원/김준석
KMID : 0360319930250020299
Abstract
Ondansetron is a new, highly selective 5-HT3 antagonist which has been shown to be highly effective in the prevention of nausea and vomiting induced by cisplatin and non-cisplatin chemotherapy. We evaluated the efficacy and safety of ondansetron
in
preventing nausea and vomiting induced by cisplatin containing chemotherapy regimen. The patients received 8 mg of ondansetron in a slow intravenous infusion 30 minutes before the administration of cisplatin, which has followed by a continous
infusion
of ondansetron for 24 hours at the rate of 1 mg/hour. At the end of the first 24 hours period, ondanseteron was administered as an oral dosage of 8 mg every 8 hours for the next 5 days. Twenty patients(14 men and 6 women) enrolled in this study
whose
mean age was 46 years old. The patients received 40 to 120 mg/㎡of cisplatin (mean 75 mg/㎡).
Nausea was controll din 60% of the patients(none:35%, mild: 25%) and emesis(vomiting and retching) was controlled in 60% of the patients(complete: 35%, major: 25%) on Day 1. On Day 2 to 6, nausea was controlled in 45% of the patients(none: 25%,
mild:
20%) and emesis was controlled in 55%(complete: 25%, major: 30%) of the patients. The side effects of ondansetron were observed in 10 patients with mild headache(25%), chest discomfort(20%), and mild fever(5%). No extrapyramidal symptom was
noted.
These results showed that ondansetron is an effective and safe agent for controlling the nausea and vomiting induced by cisplatin treatment.
키워드
원문 및 링크아웃 정보
등재저널 정보